Results 21 to 30 of about 115,017 (359)

Predicting the Risk of Right Ventricular Failure in Patients Undergoing Left Ventricular Assist Device Implantation

Circulation: Heart Failure, 2020
Supplemental Digital Content is available in the text. Background: Right ventricular failure (RVF) is a cause of major morbidity and mortality after left ventricular assist device (LVAD) implantation.
C. Frankfurter, M. Molinero, J. Vishram-Nielsen, F. Foroutan, S. Mak, V. Rao, F. Billia, A. Orchanian‐Cheff, A. Alba   +8 more
semanticscholar   +1 more source

Left Ventricular Assist Device-Related Complications

Journal of Cardiovascular Emergencies, 2020
Left ventricular assist device (LVAD) has emerged as a safe, durable, and revolutionary therapy for end-stage heart failure patients. Despite the appearance of newer-generation devices that have improved patient outcomes, the burden of adverse events ...
Clement Alexandra, Anghel Larisa, Sascău Radu, Stătescu Cristian   +3 more
doaj   +1 more source

Left Ventricular Assist Device (LVAD) Implantation and Renal Dysfunction [PDF]

Ķazaķstannyṇ Klinikalyķ Medicinasy, 2018
Pathophysiological, pathomorphological and functional changes in the kidneys after left ventricular assist device implantation have not yet been fully understood and represent an actual problem of our time.
Assem Nogaibayeva, Bagdat Sultanova, Myrzabek Makhmutov   +2 more
doaj   +1 more source

Outcomes of Hospitalizations for Cardiogenic Shock at Left Ventricular Assist Device Versus Non–Left Ventricular Assist Device Centers

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Cardiogenic shock (CS) is a complex syndrome associated with high morbidity and mortality. In recent years, many US hospitals have formed multidisciplinary shock teams capable of rapid diagnosis and triage. Because of preexisting collaborative
Joseph I. Wang, Daniel Y. Lu, MHS, Dmitriy N. Feldman, Stephen A. McCullough, Parag Goyal, Maria G. Karas, Irina Sobol, Evelyn M. Horn, Luke K. Kim, Udhay Krishnan   +10 more
doaj   +1 more source

Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature. [PDF]

Eur J Breast Health
Alanyalı S, Karaman E, Köylü M, Kahraman Ü, Nalbantgil S.   +4 more
europepmc   +3 more sources

Novel percutaneous dual-lumen cannula-based right ventricular assist device provides effective support for refractory right ventricular failure after left ventricular assist device implantation.

Interactive Cardiovascular and Thoracic Surgery, 2020
OBJECTIVES Right heart failure after left ventricular assist device (LVAD) implantation is associated with significant morbidity and mortality. A new generation of percutaneous right ventricular assist devices (RVADs) may mitigate the need for invasive ...
M. Salna, A. Garan, Ajay J. Kirtane, D. Karmpaliotis, P. Green, H. Takayama, Joseph E Sanchez, P. Kurlansky, M. Yuzefpolskaya, P. Colombo, Y. Naka, K. Takeda   +11 more
semanticscholar   +1 more source

A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients [PDF]

, 2014
BACKGROUND: Thrombotic events are a common complication of left ventricular assist device placement and warrant prophylactic anticoagulation. Heparin is the most common anticoagulant used for prophylaxis of thrombotic events in left ventricular assist ...
Aesha Shah, Nicholas Tillman, Scott T Benken, Suhuir Dajani, Toby Thomas   +4 more
core   +1 more source

Experience with percutaneous right ventricular support in the early post-left ventricular assist device implantation period (clinical case report and literature reviews)

Вестник трансплантологии и искусственных органов, 2023
Implantable left ventricular assist device (LVAD) is a state-of-the-art treatment for adults and children with end-stage heart failure. The early and late period after LVAD implantation can be severely complicated.
V. N. Poptsov, E. A. Spirina, D. V. Ryabtsev, A. K. Solodovnikova, A. S. Epremian   +4 more
doaj   +1 more source

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients The ROADMAP Study 2-Year Results [PDF]

, 2017
OBJECTIVES The authors sought to provide the pre-specified primary endpoint of the ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients) trial at 2 years ...
Boyle, Andrew J., Bruckner, Brian A., Chuang, Joyce, Estep, Jerry D., Farrar, David J., Haas, Donald C., Horstmanshof, Douglas A., Kasirajan, Vigneshwar, Lee, Sangjin, Long, James W., Milano, Carmelo A., Rogers, Joseph G., Selzman, Craig H., Shah, Keyur B., Starling, Randall C., Stehlik, Josef   +15 more
core   +2 more sources

Immunocompetent cells in durable ventricular assist device-implanted non-ischaemic dilated cardiomyopathy. [PDF]

, 2022
OBJECTIVE: Because the presence of immunocompetent cells in the myocardium is associated with the pathological stage and/or myocardial viability, we explored relationships between functional recovery after left ventricular assist device implantation and ...
Fujita, T, Fukui, T, Fukushima, N, Fukushima, S, Ishibashi-Ueda, H, Kakuta, T, Koga-Ikuta, A, Suzuki, K, Tadokoro, N, Watanabe, T   +9 more
core   +1 more source